Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| GRĂ©PEC-17409 | Other Grant/Funding Number | Cancer Research Society & FRQ-S |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| McGill University Health Centre/Research Institute of the McGill University Health Centre | OTHER |
| Centre de recherche du Centre hospitalier universitaire de Sherbrooke | OTHER |
| Centre de Recherche du Centre Hospitalier de l'Université de Montréal |
Not provided
Not provided
Not provided
Not provided
The risk of prostate cancer is associated with lifestyle habits, such as diet and physical activity. Indeed, results of numerous studies suggest links between obesity, diabetes, inflammation and androgen and estrogen metabolism in the pathogenesis of prostate cancer.
The goal of BIOCaPPE study (Biomarkers and Prostate Cancer/ Prevention and Environment) is to identify biomarkers of prostate cancer risk that are potentially modifiable by environmental exposures (e.g. diet and physical activity).
A selection of few of the most promising biological markers will be evaluated in a cohort of more than 2000 men at high-risk of prostate cancer.
Such biomarkers would provide a practical approach to identify men at high risk of prostate cancer who could benefit from interventions aiming at reducing their risk. The biomarkers would also be useful to monitor the efficacy of the interventions on patient's lifestyle.
The main objective of the proposed research project is to assess the association between five candidate biological markers potentially modifiable by environmental exposures (diet and physical activity) and the two-year risk of prostate cancer in a newly recruited cohort of men at high-risk of prostate cancer showing no evidence of cancer.
Four hospitals in the province of Quebec (Canada) participate to the recruitment of 2,055 men at high-risk for prostate cancer, i.e. men who had a first negative prostate biopsy or whose Prostatic Specific Antigen (PSA) level is between 2.5 and 10 ng/mL without previous prostate biopsy.
The candidate biomarkers that will be tested are:
A biobank, composed of biological material (whole blood, plasma, serum, lymphocyte layer and excess tissue collected from prostate biopsy or prostate surgery) and clinical data is being created. Questionnaires are used to compile information on socio-demographic aspects, family and personal medical history, quality of life, lifestyle like food and sexual habits.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Men at high-rik of prostate cancer | Lifestyle questionnaires such as diet questionnaire, physical activities questionnaires, quality of life , Follows up 1 year and 2 years after the enrollment, Anthropometric measures during the first visit , Blood withdrawal for laboratory biomarkers analysis After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lifestyle questionnaires | Other |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Biomarkers and modifiable exposure environment | Assess the association between five candidate biological markers potentially modifiable by environmental exposures, mainly diet and physical activity, with the two-year risk of prostate cancer in men at risk for prostate cancer as previously defined. | An average of 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Study biobank | Biobank of biological samples, clinical data and data from the lifestyle questionnaires | Through study completion, every year up to 2 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Eligible participants for this prospective cohort study are men at risk for prostate cancer.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Vincent FRADET, MD, PhD | CHU de Québec-Université Laval | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre de Recherche du Centre Hospitalier de l'Université de Montréal | Montreal | Quebec | H2X 0A9 | Canada | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42209010 | Derived | Moussa H, Tourigny R, Robitaille K, Bussieres V, Fadel J, Ben Souilah F, Diabate L, Hovington H, Bettan L, Lacombe L, Dujardin T, Lodde M, Toren P, Aprikian A, Saad F, Carmel M, Jeldres C, Lamarche B, Bergeron A, Fradet Y, Fradet V; Network BIOCaPPE. Cohort profile: BioCaPPE (Biomarkers of Prostate Cancer/Prevention and Environment) - a Canadian multicentre prospective study of lifestyle and candidate biomarkers in relation to prostate cancer risk. BMJ Open. 2026 May 28;16(5):e111118. doi: 10.1136/bmjopen-2025-111118. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
serum, plasma, whole blood and blood DNA samples and excess tissue collected from prostate biopsy or prostate surgery
| Prostate Biopsy | Diagnostic Test | Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer. |
|
|
| McGill University Health Center |
| Montreal |
| Quebec |
| H4A 3J1 |
| Canada |
| CHU de Quebec- Université Laval | Québec | Quebec | G1R3S1 | Canada |
| Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Sherbrooke | Quebec | J1H 5N4 | Canada |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |